Enovis (NYSE:ENOV) Shares Gap Up on Insider Buying Activity

Shares of Enovis Corporation (NYSE:ENOV) gapped up before the market opened on Friday following insider buying activity. The stock had previously closed at $27.64, but opened at $28.65. Enovis shares last traded at $28.3610, with a volume of 65,747 shares.

Specifically, Director Angela S. Lalor acquired 870 shares of Enovis stock in a transaction on Wednesday, November 11th. The shares were bought at an average price of $28.86 per share, for a total transaction of $25,108.20. Following the completion of the purchase, the director directly owned 33,243 shares in the company, valued at $959,392.98. This trade represents a 2.69% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Angela S. Lalor bought 887 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The stock was bought at an average cost of $28.28 per share, with a total value of $25,084.36. Following the transaction, the director directly owned 32,373 shares of the company’s stock, valued at approximately $915,508.44. This trade represents a 2.82% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Analysts Set New Price Targets

ENOV has been the subject of a number of recent research reports. Wells Fargo & Company increased their target price on Enovis from $33.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. Needham & Company LLC boosted their price target on Enovis from $34.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Citizens Jmp lowered their price objective on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research report on Wednesday, September 2nd. Finally, BMO Capital Markets set a $27.00 price objective on shares of Enovis in a research note on Tuesday, September 1st. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.62.

Enovis News Summary

Here’s some of the latest news about ENOV:

• Positive Sentiment: Directors Angela S. Lalor and Sharon Wienbar bought a combined 3,531 shares for roughly $100,000 in purchases dated November 10–11, increasing their holdings. Insider buying can indicate confidence, though the transactions are relatively small and are not a guarantee of future performance. Lalor SEC filing Wienbar SEC filing
• Neutral Sentiment: Enovis management is scheduled to present at the Jefferies Global Healthcare Conference in London on November 17. The event could provide investors with additional context, but the announcement included no new guidance or business details. Conference announcement

Enovis Stock Performance

The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -3.05 and a beta of 1.31. The stock’s fifty day moving average is $20.36 and its two-hundred day moving average is $23.19. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.08 and a current ratio of 2.15.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The firm had revenue of $558.73 million during the quarter, compared to analyst estimates of $557.12 million. During the same period in the previous year, the business posted $0.75 EPS. Enovis’s revenue was up 1.8% on a year-over-year basis. On average, analysts expect that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enovis

A number of hedge funds have recently made changes to their positions in ENOV. Paradigm Capital Management Inc. NY acquired a new position in shares of Enovis during the second quarter worth approximately $28,533,000. Bank of America Corp DE acquired a new stake in Enovis in the 2nd quarter valued at approximately $11,502,000. Private Management Group Inc. increased its position in Enovis by 31.3% in the 3rd quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock valued at $32,748,000 after acquiring an additional 427,347 shares during the period. Man Group plc bought a new stake in Enovis during the 2nd quarter valued at $8,711,000. Finally, Front Street Capital Management Inc. boosted its position in Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after acquiring an additional 384,124 shares during the period. Institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.